Cyclin A2 antibody
GTX103042
ApplicationsImmunoFluorescence, ImmunoPrecipitation, Western Blot, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
TargetCCNA2
Overview
- SupplierGeneTex
- Product NameCyclin A2 antibody
- Delivery Days Customer9
- Application Supplier NoteWB: 1:500-1:3000. ICC/IF: 1:100-1:1000. IHC-P: 1:100-1:1000. IP: 1:100-1:500. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsImmunoFluorescence, ImmunoPrecipitation, Western Blot, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
- CertificationResearch Use Only
- ClonalityPolyclonal
- Concentration0.73 mg/ml
- ConjugateUnconjugated
- Gene ID890
- Target nameCCNA2
- Target descriptioncyclin A2
- Target synonymsCCN1, CCNA, cyclin-A2, cyclin-A
- HostRabbit
- IsotypeIgG
- Protein IDP20248
- Protein NameCyclin-A2
- Scientific DescriptionThe protein encoded by this gene belongs to the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance through the cell cycle. Cyclins function as regulators of CDK kinases. Different cyclins exhibit distinct expression and degradation patterns which contribute to the temporal coordination of each mitotic event. In contrast to cyclin A1, which is present only in germ cells, this cyclin is expressed in all tissues tested. This cyclin binds and activates CDC2 or CDK2 kinases, and thus promotes both cell cycle G1/S and G2/M transitions. [provided by RefSeq]
- Storage Instruction-20°C or -80°C,2°C to 8°C
- UNSPSC12352203
References
- Cardile A, Zanrè V, Campagnari R, et al. Hyperforin Elicits Cytostatic/Cytotoxic Activity in Human Melanoma Cell Lines, Inhibiting Pro-Survival NF-κB, STAT3, AP1 Transcription Factors and the Expression of Functional Proteins Involved in Mitochondrial and Cytosolic Metabolism. Int J Mol Sci. 2023,24(2). doi: 10.3390/ijms24021263Read this paper
- Gupta RK, Mlcochova P. Cyclin D3 restricts SARS-CoV-2 envelope incorporation into virions and interferes with viral spread. EMBO J. 2022,41(22):e111653. doi: 10.15252/embj.2022111653Read this paper
- Zanrè V, Campagnari R, Cerulli A, et al. Salviolone from Salvia miltiorrhiza Roots Impairs Cell Cycle Progression, Colony Formation, and Metalloproteinase-2 Activity in A375 Melanoma Cells: Involvement of P21(Cip1/Waf1) Expression and STAT3 Phosphorylation. Int J Mol Sci. 2022,23(3). doi: 10.3390/ijms23031121Read this paper
- Chen SY, Chao CN, Huang HY, et al. Auranofin induces urothelial carcinoma cell death via reactive oxygen species production and synergy with cisplatin. Oncol Lett. 2022,23(2):61. doi: 10.3892/ol.2021.13179Read this paper
- Hinds JW, Ditano JP, Eastman A. Inhibition of Protein Synthesis Induced by CHK1 Inhibitors Discriminates Sensitive from Resistant Cancer Cells. ACS Pharmacol Transl Sci. 2021,4(4):1449-1461. doi: 10.1021/acsptsci.1c00150Read this paper
- Pietilä EA, Gonzalez-Molina J, Moyano-Galceran L, et al. Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance. Nat Commun. 2021,12(1):3904. doi: 10.1038/s41467-021-24009-8Read this paper
- Ditano JP, Sakurikar N, Eastman A. Activation of CDC25A phosphatase is limited by CDK2/cyclin A-mediated feedback inhibition. Cell Cycle. 2021,20(13):1308-1319. doi: 10.1080/15384101.2021.1938813Read this paper
- Javary J, Allain N, Ezzoukhry Z, et al. Reptin/RUVBL2 is required for hepatocyte proliferation in vivo, liver regeneration and homeostasis. Liver Int. 2021,41(6):1423-1429. doi: 10.1111/liv.14886Read this paper
- Fu H, Zhang Y, Chen Y, et al. CSN1 facilitates proliferation and migration of hepatocellular carcinoma cells by upregulating cyclin A2 expression. Mol Med Rep. 2021,23(1):pii: 46. doi: 10.3892/mmr.2020.11684.Read this paper
- Zhang G, Li L, Bi J, et al. Targeting DNA and mutant p53 by a naphthalimide derivative, NA20, exhibits selective inhibition in gastric tumorigenesis by blocking mutant p53-EGFR signaling pathway. Eur J Pharmacol. 2020,887:173584. doi: 10.1016/j.ejphar.2020.173584Read this paper


